Exelixis (EXEL) Other Non-Current Assets (2010 - 2022)
Exelixis' (EXEL) quarterly Other Non-Current Assets came in at $280.0 million in Q3 2022, up 107.91% year-on-year from $134.7 million in Q3 2021, and little changed quarter-over-quarter from $279.7 million in Q3 2022.
Exelixis (EXEL) Other Non-Current Assets (2010 - 2022) Analysis & Trends
Exelixis' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $280.0 million for Q3 2022.
- On a quarterly basis, Other Non-Current Assets rose 107.91% year-over-year to $280.0 million in Q3 2022; TTM through Sep 2022 was $280.0 million, a 107.91% increase from a year earlier, with the FY2021 full-year figure at $131.0 million, up 78.46% from the prior year.
- Other Non-Current Assets was little changed at $280.0 million in Q3 2022 per EXEL's latest filing, from $279.7 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $280.0 million in Q3 2022 and bottomed at $1.1 million in Q2 2018.
- The 5-year median for Other Non-Current Assets is $60.5 million (2020), against an average of $82.3 million.
- Across the five-year window, Other Non-Current Assets retreated 26.67% in 2019 and surged 5110.18% in 2020, its largest moves.
- Year by year, Other Non-Current Assets stood at $8.3 million in 2018, then retreated by 12.34% to $7.3 million in 2019, then jumped by 854.99% to $69.4 million in 2020, then surged by 88.74% to $131.0 million in 2021, then jumped by 113.74% to $280.0 million in 2022.
- Per Business Quant, the three latest EXEL Other Non-Current Assets figures stand at $280.0 million (Q3 2022), $279.7 million (Q3 2022), and $139.0 million (Q2 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 280.01 Mn |
| Jul 1, 2022 | 279.71 Mn |
| Apr 1, 2022 | 138.99 Mn |
| Dec 31, 2021 | 131.00 Mn |
| Oct 1, 2021 | 134.68 Mn |
| Jul 2, 2021 | 134.93 Mn |
| Apr 2, 2021 | 124.68 Mn |
| Jan 1, 2021 | 73.41 Mn |
| Oct 2, 2020 | 69.41 Mn |
| Jul 3, 2020 | 60.50 Mn |
| Apr 3, 2020 | 57.31 Mn |
| Jan 3, 2020 | 53.15 Mn |
| Sep 27, 2019 | 7.27 Mn |
| Jun 28, 2019 | 5.76 Mn |
| Mar 29, 2019 | 1.10 Mn |
| Dec 28, 2018 | 8.29 Mn |
| Sep 28, 2018 | 1.10 Mn |
| Jun 29, 2018 | 1.10 Mn |
| Mar 30, 2018 | 1.50 Mn |
| Dec 29, 2017 | 4.65 Mn |